Results 11 to 20 of about 35,838 (264)

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and
J. Cortés, Sung-Bae Kim, Wei-Pang Chung, S. Im, Yeon-Hee Park, R. Hegg, Min Hwan Kim, L. Tseng, V. Petry, Chi-Feng Chung, H. Iwata, E. Hamilton, G. Curigliano, Bing-he Xu, Chiun-Sheng Huang, J. Kim, J. Chiu, J. Pedrini, Caleb Lee, Yali Liu, J. Cathcart, E. Bako, S. Verma, S. Hurvitz   +23 more
semanticscholar   +6 more sources

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2021
BACKGROUND Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC).
Bob T. Li, E. Smit, Y. Goto, K. Nakagawa, H. Udagawa, J. Mazières, M. Nagasaka, L. Bazhenova, A. Saltos, E. Felip, J. Pacheco, M. Pérol, L. Paz-Ares, K. Saxena, R. Shiga, Yingkai Cheng, S. Acharyya, P. Vitazka, J. Shahidi, D. Planchard, P. Jänne   +20 more
semanticscholar   +8 more sources

Trastuzumab deruxtecan improves survival [PDF]

Nature Reviews Clinical Oncology, 2020
Peter Sidaway
openalex   +4 more sources

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer [PDF]

Indian Journal of Medical and Paediatric Oncology, 2019
Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj   +2 more sources

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

Frontiers in Pharmacology, 2022
Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen, Xi Yan, Xi Yan   +6 more
doaj   +3 more sources

Efficacy and safety of trastuzumab deruxtecan therapy

Onkologija
Antibody-drug conjugates (ADCs) are a new generation of drugs that currently represent one of the most effective treatment options for cancer. ADCs target a specific target (antigen) that is selectively expressed on a tumour cell.
Nina Privšek, Simona Borštnar, Cvetka Grašič Kuhar   +2 more
doaj   +2 more sources

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

CNS Oncology, 2022
Antibody–drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood–brain tumor barrier ...
Nelson S Moss, Umberto Tosi, Bianca D Santomasso, Kathryn Beal, Shanu Modi   +4 more
doaj   +3 more sources

Trastuzumab Deruxtecan in Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2022
Bob T. Li, Egbert F. Smit, Pasi A. Jänne   +2 more
openalex   +5 more sources

Trastuzumab deruxtecan in breast cancer.

Critical Reviews in Oncology/Hematology
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload (DXd). The high drug-to-antibody ratio (8:1) ensures a high DXd concentration is delivered to target tumour cells ...
Miguel Martín, A. Pandiella, E. Vargas-Castrillón, Elena Díaz-Rodríguez, Teresa Iglesias-Hernangómez, Concha Martínez Cano, Inés Fernández-Cuesta, Elena Winkow, M. F. Perelló   +8 more
semanticscholar   +4 more sources

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

JTO Clinical and Research Reports, 2022
Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC.
Mariona Riudavets, MD, PhD, Arshid Azarine, MD, MSc, Sondes Smaali, MD, Young-Wouk Kim, MD, Vincent Thomas de Montpréville, MD, Alina Miruna Grecea, MD, Charles Naltet, MD, Annas Gazzah, MD, David Planchard, MD, PhD   +8 more
doaj   +1 more source